Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Clinical characteristics and outcomes of Richter transformation: Experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2019 Jun 13. pii: haematol.2019.224121. doi: 10.3324/haematol.2019.224121. [Epub ahead of print]

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients.

Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD.

Br J Haematol. 2013 Sep;162(6):774-82. doi: 10.1111/bjh.12458. Epub 2013 Jul 11.

4.

Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group.

Tadmor T, Shvidel L, Goldschmidt N, Ruchlemer R, Fineman R, Bairey O, Rahimi-Levene N, Herishanu Y, Yuklea M, Arad A, Aviv A, Polliack A.

Anticancer Res. 2014 Feb;34(2):785-90.

PMID:
24511013
5.

Richter transformation in 16 of 149 Chinese patients with chronic lymphocytic leukemia.

Fan L, Wang L, Zhang R, Fang C, Zhu DX, Wang YH, Zou ZJ, Li JY, Xu W.

Leuk Lymphoma. 2012 Sep;53(9):1749-56. doi: 10.3109/10428194.2012.664845. Epub 2012 Mar 13.

PMID:
22329349
6.

A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.

Rogers KA, Huang Y, Ruppert AS, Salem G, Stephens DM, Heerema NA, Andritsos LA, Awan FT, Byrd JC, Flynn JM, Maddocks KJ, Jones JA.

Br J Haematol. 2018 Jan;180(2):259-266. doi: 10.1111/bjh.15035. Epub 2017 Nov 28.

PMID:
29193006
7.

Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.

Khan M, Siddiqi R, Thompson PA.

Ann Hematol. 2018 Jan;97(1):1-15. doi: 10.1007/s00277-017-3149-9. Epub 2017 Oct 23. Review.

PMID:
29063177
8.

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC.

Blood Adv. 2017 Aug 21;1(19):1584-1588. doi: 10.1182/bloodadvances.2017007302. eCollection 2017 Aug 22.

9.

Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients.

Morscio J, Bittoun E, Volders N, Lurquin E, Wlodarska I, Gheysens O, Vandenberghe P, Verhoef G, Demaerel P, Dierickx D, Sagaert X, Janssens A, Tousseyn T.

J Hematop. 2016 May 21;9:113-120. doi: 10.1007/s12308-016-0273-8. eCollection 2016. Erratum in: J Hematop. 2018 May 4;11(2):65.

10.

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.

McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM.

Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.

11.

Clinical, pathological, and biological characterization of Richter syndrome developing after ibrutinib treatment for relapsed chronic lymphocytic leukemia.

Innocenti I, Rossi D, Trapè G, Autore F, Larocca LM, Gomes V, Cerri M, Falcucci P, Sica S, Gaidano G, Laurenti L.

Hematol Oncol. 2018 Feb 27. doi: 10.1002/hon.2502. [Epub ahead of print]

PMID:
29484684
12.

[Richter syndrome: clinical characteristics and treatment experiences].

Li ZJ, Xu Y, Zhang PH, Liu W, Yi SH, Zou DH, Qi JY, Zhao YZ, Qiu LG.

Zhonghua Yi Xue Za Zhi. 2012 Dec 11;92(46):3254-6. Chinese.

PMID:
23328508
13.

Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway.

Lenartova A, Randen U, Johannesen TB, Tjønnfjord GE.

Cancer Epidemiol. 2019 Jun;60:128-133. doi: 10.1016/j.canep.2019.04.002. Epub 2019 Apr 12.

PMID:
30986631
14.

Richter transformation in the era of novel agents.

Ding W.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):256-263. doi: 10.1182/asheducation-2018.1.256. Review.

PMID:
30504319
15.

Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience.

Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e35-e39. doi: 10.1016/j.clml.2017.10.002. Epub 2017 Oct 12.

PMID:
29126867
16.

How we treat Richter syndrome.

Parikh SA, Kay NE, Shanafelt TD.

Blood. 2014 Mar 13;123(11):1647-57. doi: 10.1182/blood-2013-11-516229. Epub 2014 Jan 13.

17.

Immunochemotherapy for Richter syndrome: current insights.

Puła B, Salomon-Perzyński A, Prochorec-Sobieszek M, Jamroziak K.

Immunotargets Ther. 2019 Feb 5;8:1-14. doi: 10.2147/ITT.S167456. eCollection 2019. Review.

18.

Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

Miyaoka M, Kikuti YY, Carreras J, Ikoma H, Hiraiwa S, Ichiki A, Kojima M, Ando K, Yokose T, Sakai R, Hoshikawa M, Tomita N, Miura I, Takata K, Yoshino T, Takizawa J, Bea S, Campo E, Nakamura N.

Mod Pathol. 2018 Feb;31(2):313-326. doi: 10.1038/modpathol.2017.134. Epub 2017 Oct 6.

19.
20.

High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.

Li S, Weiss VL, Wang XJ, Desai PA, Hu S, Yin CC, Tang G, Reddy NM, Medeiros LJ, Lin P.

Am J Surg Pathol. 2016 Feb;40(2):253-61. doi: 10.1097/PAS.0000000000000542.

PMID:
26448193

Supplemental Content

Support Center